SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors

Primary hepatic neuroendocrine tumors (PHNETs) are extremely rare NETs originating from the liver. These tumors are associated with heterogeneous prognosis, and few treatment targets for PHNETs have been identified. Because the major genetic alterations in PHNET are still largely unknown, we performed whole‐exome sequencing of 22 paired tissues from PHNET patients and identified 22 recurring mutations of somatic genes involved in the following activities: epigenetic modification (BPTF, MECP2 and WDR5), cell cycle (TP53, ATM, MED12, DIDO1 and ATAD5) and neural development (UBR4, MEN1, GLUL and GIGYF2). Here, we show that TP53 and the SET domain containing the 1B gene (SETD1B) are the most frequently mutated genes in this set of samples (3/22 subjects, 13.6%). A biological analysis suggests that one of the three SETD1B mutants, A1054del, promotes cell proliferation, migration and invasion compared to wild‐type SETD1B. Our work unveils that SETD1B A1054del mutant is functional in PHNET and implicates genes including TP53 in the disease. Our findings thus characterize the mutational landscapes of PHNET and implicate novel gene mutations linked to PHNET pathogenesis and potential therapeutic targets.

[1]  Anna L. Brown,et al.  Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. , 2018, Blood.

[2]  A. F. Stewart,et al.  The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice , 2018, eLife.

[3]  T. Ogata,et al.  De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism , 2018, Human Genetics.

[4]  A. F. Stewart,et al.  Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program , 2017, Development.

[5]  Weiwei Yang,et al.  Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis , 2017, Current opinion in hematology.

[6]  X. Matías-Guiu,et al.  Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma , 2017, International journal of cancer.

[7]  B. Honig,et al.  Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode , 2016, Nature.

[8]  Shuai Li,et al.  Structural basis for activity regulation of MLL family methyltransferases , 2016, Nature.

[9]  A. Sánchez Alvarado,et al.  Set1 and MLL1/2 Target Distinct Sets of Functionally Different Genomic Loci In Vivo. , 2015, Cell reports.

[10]  Marco Y. Hein,et al.  A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances , 2015, Cell.

[11]  Ju-Seog Lee The mutational landscape of hepatocellular carcinoma , 2015, Clinical and molecular hepatology.

[12]  Q. Ye,et al.  HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion , 2015, Scientific Reports.

[13]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[14]  B. Vainer,et al.  Genetic analysis of an orbital metastasis from a primary hepatic neuroendocrine carcinoma. , 2014, Oncology reports.

[15]  Rochelle L. Tiedemann,et al.  Impact of human MLL/COMPASS and polycomb complexes on the DNA methylome , 2014, Oncotarget.

[16]  P. Ruszniewski,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[17]  Qiang Feng,et al.  Identification of genomic alterations in oesophageal squamous cell cancer , 2014, Nature.

[18]  Jiaqian Wang,et al.  Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1 , 2013, Nature Communications.

[19]  R. Roeder,et al.  SET1 and p300 Act Synergistically, through Coupled Histone Modifications, in Transcriptional Activation by p53 , 2013, Cell.

[20]  J. Wysocka,et al.  Modification of enhancer chromatin: what, how, and why? , 2013, Molecular cell.

[21]  Jason Li,et al.  CONTRA: copy number analysis for targeted resequencing , 2012, Bioinform..

[22]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[23]  A. Branch,et al.  HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. , 2011, Seminars in liver disease.

[24]  Y. Li,et al.  Chromatin boundaries require functional collaboration between the hSET1 and NURF complexes. , 2011, Blood.

[25]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[26]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[27]  D. Skalnik,et al.  Identification and Characterization of the Human Set1B Histone H3-Lys4 Methyltransferase Complex* , 2007, Journal of Biological Chemistry.

[28]  C. Béroud,et al.  Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein , 2002, Human mutation.

[29]  A. Miyauchi,et al.  Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. , 1998, Journal of medical genetics.

[30]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[31]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[32]  G. Gores,et al.  Hepatocellular carcinoma , 2016, Nature Reviews Disease Primers.

[33]  S. Yonemitsu,et al.  A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity. , 2015, Internal medicine.

[34]  Yang Zhang,et al.  I‐TASSER: Fully automated protein structure prediction in CASP8 , 2009, Proteins.

[35]  D. Eisenberg,et al.  A method to identify protein sequences that fold into a known three-dimensional structure. , 1991, Science.